Pyrimidine classical cannabinoid compounds and related methods of use

Abstract

Disclosed are compounds of the formula I: wherein R 1 , R 2 , V, W, X, Y and Z are as defined herein. The compounds can be used in the treatment of disorders mediated by the cannabinoid receptors, such as, for example, inflammation.

What is claimed is: 
     
         1 . A method of treating cancer mediated by a cannabinoid receptor comprising contacting said receptor with a compound in an amount to treat said cannabinoid receptor-mediated disorder, wherein the compound is of the formula 
       
         
           
           
               
               
           
         
         wherein 
         represents an optional double bond wherein the ring that optionally contains it is selected from hexahydro, 6a,10a-dehydro, 8,9-dehydro, and 9,10-dehydro; 
         ----- Y is selected from S, O, CH 2 , CH(CH 3 ), CH(OH), C(CH 3 )(OH), C(CH 3 ) 2 , C(—U(CH 2 ) n U—), C(O), NH, S(O), and S(O) 2 ; 
         n is an integer ≧1; 
         U is selected from CH 2 , S, and O; 
         Z is selected from H, substituted and unsubstituted alkyl, and
 cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, and heterocycloalkylalkyl, wherein each alkyl portion is optionally substituted and the ring portion of each is optionally substituted with one, two, three, four or five substituents; and 
 
         R 1  is selected from H and substituted and unsubstituted alkyl. 
       
     
     
         2 . A method according to  claim 1  wherein
 R 1  is selected from H and alkyl; 
 Y is selected from carbonyl, dimethylmethylene and hydroxymethylene; and 
 Z is selected from substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted phenyl, and substituted or unsubstituted thiophenyl. 
 
     
     
         3 . A method according to  claim 2  wherein Z is alkyl, cycloalkyl, phenyl or thiophenyl. 
     
     
         4 . A method according to  claim 3  wherein Z is hexyl, cyclohexyl, phenyl or thiophenyl. 
     
     
         5 . A method according to  claim 2  wherein Y is dimethylmethylene. 
     
     
         6 . A method according to  claim 2  wherein the ring having ----- is hexahydro or 6a,10a-dehydro. 
     
     
         7 . A method according to  claim 1  wherein the compound is selected from
 a) 3-Benzyl-6,6,9-trimethyl-6a,7,8,9,10,10a-hexahydro-6H-isochromeno[3,4-d]pyrimidin-1-ol; 
 b) (6aS,9R,10aR)-6,6,9-Trimethyl-3-(2-methyloctan-2-yl)-6a,7,8,9,10,10a-hexahydro-6H-isochromeno[3,4-d]pyrimidin-1-ol; 
 c) (6aS,9R,10aR)-6,6,9-trimethyl-3-(2-phenylpropan-2-yl)-6a,7,8,9,10,10a-hexahydro-6H-isochromeno[3,4-d]pyrimidin-1-ol; 
 d) (6aS,9R,10aR)-3-(2-Cyclohexylpropan-2-yl)-6,6,9-trimethyl-6a,7,8,9,10,10a-hexahydro-6H-isochromeno[3,4-d]pyrimidin-1-ol; 
 e) (6aS,9R,10aR)-6,6,9-Trimethyl-3-(2-(thiophen-2-yl)propan-2-yl)-6a,7,8,9,10,10a-hexahydro-6H-isochromeno[3,4-d]pyrimidin-1-ol; 
 f) (6aR,9S,10aS)-6,6,9-Trimethyl-3-(2-phenylpropan-2-yl)-6a,7,8,9,10,10a-hexahydro-6H-isochromeno[3,4-d]pyrimidin-1-ol; 
 g) 3-Benzyl-6,6,9-trimethyl-tetrahydro-6H-isochromeno[3,4-d]pyrimidin-1-ol; and 
 h) 3-Benzyl-6,6,9-trimethyl-7,8,9,10-tetrahydro-6H-isochromeno[3,4-d]pyrimidin-1-ol. 
 
     
     
         8 . A method according to  claim 1  wherein the cannabinoid receptor is selected from CB-1 and CB-2.